Joe Biden (AP Images)

Covid-19 roundup: Mod­er­na has filed for vac­cine use in chil­dren; Claim­ing lead­er­ship to com­bat Covid-19, US pledges to do­nate 500M dos­es of Pfiz­er/BioN­Tech vac­cines through CO­V­AX

Just days af­ter Mod­er­na’s vac­cine was sub­mit­ted for ap­proval for use in chil­dren in the EU and Cana­da, the com­pa­ny has an­nounced it has filed for emer­gency use au­tho­riza­tion with the FDA for the ad­min­is­tra­tion in teens be­tween 12 and 18.

Mod­er­na an­nounced in May that its Phase II/III study of the vac­cine in ado­les­cents met the pri­ma­ry end­points in near­ly 2,500 pa­tients, show­ing an ef­fi­ca­cy of 100% against se­vere symp­to­matic Covid-19. Be­cause chil­dren are less like­ly to de­vel­op se­ri­ous side ef­fects, the tri­al al­so looked at milder cas­es than ex­am­ined in the adult study. The study found that the vac­cine was 93% ef­fec­tive at stop­ping mild cas­es 14 days af­ter pa­tients were dosed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.